You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HR HER2- Breast Cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Situation of Chinese County Population With Breast Cancer

Not yet recruiting
  • Breast Cancer
  • +2 more
  • pathological stage
  • Xinxiang, Henan, China
    The First Affiliated Hospital of Xinxiang Medical University
Sep 13, 2022

Sentinel Lymph Node Biopsy in Early-Stage, Palpable

Recruiting
  • Breast Cancer
  • Breast surgery
  • Hartford, Connecticut
  • +9 more
Jan 27, 2023

Breast Tumors, Brain Tumors, Tumors by Site Trial (Abemaciclib, Elacestrant)

Recruiting
  • Breast Neoplasms
  • +7 more
  • Canton, Ohio
    Gabrail Cancer Center
Jan 24, 2023

Breast Cancer Trial (Gedatolisib, Palbociclib, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Aug 12, 2022

Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin+Anlotinib
  • (no location specified)
Aug 14, 2023

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023

Ribociclib in Combination With Hormonal Therapy in HR+/HER2-

Not yet recruiting
  • Breast Cancer
  • ribociclib
  • (no location specified)
Oct 10, 2023

Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Jie Ge
Aug 20, 2023

Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in Netherlands (Fasting

Not yet recruiting
  • Fasting Mimicking Diet
  • +5 more
  • Fasting Mimicking diet program
  • Alkmaar, Netherlands
  • +14 more
Aug 15, 2022

Breast Cancer Trial in China, United States (Afuresertib)

Recruiting
  • Breast Cancer
  • Santa Monica, California
  • +11 more
Nov 30, 2022

Breast Cancer, Chemo Effect Trial (Capecitabine)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • (no location specified)
Mar 9, 2022

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • (no location specified)
Apr 12, 2023

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jun 5, 2023

Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast

Completed
  • HR+/HER2- Advanced or Metastatic Breast Cancer
    • Dublin, Ireland
      Novartis Pharmaceuticals
    May 2, 2023

    Metastatic Breast Cancer, Unresectable Breast Cancer Trial in Saint Louis (DiviTum® TKa assay, CDK4/6 + Endocrine therapy)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Unresectable Breast Cancer
    • DiviTum® TKa assay
    • CDK4/6 + Endocrine therapy
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 27, 2023

    Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

    Not yet recruiting
    • Breast Cancer
    • Advanced Breast Cancer
    • Everolimus 10 mg
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jul 14, 2023

    HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

    Not yet recruiting
    • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
    • PERT-IJS plus trastuzumab, carboplatin and docetaxel
    • Perjeta plus trastuzumab, carboplatin and docetaxel
    • (no location specified)
    Sep 21, 2023

    Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

    Not yet recruiting
    • Advanced HR+ HER2 Negative Breast Carcinoma
    • (CDK)4/6 inhibitor
    • (no location specified)
    Sep 27, 2022

    Risarg® Combined With Endocrine Therapy or Chemotherapy in

    Not yet recruiting
    • HR+HER2- Advanced Breast Cancer
    • Ribociclib
    • Combination chemotherapy
    • (no location specified)
    Nov 20, 2023

    Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
      • Tuebingen, Germany
        Department of Women's Health
      Jun 1, 2023